saRNA provide a new way of stimulating a cell’s messenger RNA (mRNA) and protein production. saRNA therapeutics hold promise for many conditions and diseases that are untreatable with today’s conventional medicines.
Harnessing a proprietary bioinformatics platform, MiNA is rapidly discovering and developing saRNA to selectively up-regulate protein expression.
saRNA recruit endogenous transcriptional complexes to a target gene, leading to increased expression of naturally processed mRNA that replicate full target gene functionality.
Gene activation by saRNA is accompanied by epigenetic changes, resulting in prolonged protein upregulation lasting weeks.
saRNA can upregulate nuclear factors, intra-cellular proteins and secreted proteins alike, in cases where genes are both naturally expressed or epigenetically silenced.
saRNA leverages decades of experience in the broader oligonucleotide field covering assay development, chemistry, manufacturing, formulation, clinical and regulatory.
MiNA has a strong IP position and is building a comprehensive patent portfolio. MiNA holds technology assignments and licenses from the Norwegian University of Science and Technology and the University of Texas Southwestern Medical Center at Dallas.